TCL Archive Group Chairmen Accept Most Changes In Terms Of Award, Object To CTEP Adjustments December 2, 1988
TCL Archive FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate. May 28, 2004
TCL Archive GSK’s Pazopanib Benefits Similar to Sunitinib; Sponsor Points to More Favorable Safety Profile August 30, 2013
